424B5 filed May 29, 2026 at 08:30 ET
Outlook Therapeutics is issuing 8,539,709 shares of common stock at $0.5855 per share to a single accredited investor, raising approximately $4.9 million in net proceeds. Concurrently, the company is amending outstanding warrants for 15,488,570 shares, reducing their exercise price from $1.78 to $0.5855 per share. The company has substantial doubt about its ability to continue as a going concern, with cash and equivalents of $7.7 million as of March 31, 2026, and expects combined funds to only sustain operations into September 2026.